Upgrade your membership to see all of the expert analysis we have published on BSTC now!
Consolidating Above 50-Day Moving Average and Prior Highs - Thursday, March 7, 2019
Biospecifics Technologies (BSTC -$0.13 or -0.19% to $67.18) is consolidating near prior highs and its 50-day moving average (DMA) line ($66.19) defining very important near-term support to watch. More damaging losses would raise concerns and trigger a technical sell signal.
BSTC was first highlighted in yellow with pivot point cited based on its 11/07/18 high plus 10 cents in the 1/18/19 mid-day report (read here). A big volume-driven gain 1/17/19 for a new high close was a reassuring sign of institutional accumulation clinching a technical buy signal. It was last shown in this FSU section on 2/05/19 with an annotated graph under the headline, "Reversed Into Red After Hitting a New High".
The thinly traded Biomed/Biotech firm's small supply (S criteria) of only 5.2 million shares in the public float can contribute to greater price volatility in the event of institutional buying or selling. The number of top-rated funds owning its shares rose from 171 in Mar '18 to 218 in Dec '18, a reassuring sign concerning the I criteria. Its current up/Down Volume Ratio of 1.4 is an unbiased indication its shares have been under accumulation over the past 50 days. It has an A Timeliness Rating and a C Sponsorship rating.
Keep in mind it it due to report earnings news on 3/14/19. Volume and volatility often increase near earnings news. Earnings increases have been above the +25% minimum guideline (C criteria) in the 4 latest quarterly comparisons through Sep '18. Its sales revenues growth rate has shown acceleration, but quarterly totals have been in the $7-8 million range, still rather minuscule in the context of all publicly traded companies.
Charts courtesy of www.stockcharts.com
Reversed Into Red After Hitting a New High - Tuesday, February 5, 2019
Biospecifics Technologies (BSTC -$0.78 or -1.14% to $67.68) reversed into the red today after briefly trading above its "max buy" level and hitting a new 52-week high. A big volume-driven gain on the prior session and new high close was a reassuring sign of institutional accumulation clinching a technical buy signal. It was first highlighted in yellow with pivot point cited based on its 11/07/18 high plus 10 cents in the 1/18/19 mid-day report (read here).
The thinly traded Biomed/Biotech firm has a small supply (S criteria) of only 5.2 million shares in the public float can contribute to greater price volatility in the event of institutional buying or selling. Disciplined investors avoid chasing stocks more than +5% above prior highs and always limit losses by selling if ever a stock falls more than -7% from their purchase price.
The number of top-rated funds owning its shares rose from 171 in Mar '18 to 221 in Dec '18, a reassuring sign concerning the I criteria. Its current up/Down Volume Ratio of 1.6 is an unbiased indication its shares have been under accumulation over the past 50 days. It has an A Timeliness Rating and a C Sponsorship rating.
Earnings increases have been above the +25% minimum guideline (C criteria) in the 4 latest quarterly comparisons through Sep '18. Its sales revenues growth rate has shown acceleration, but quarterly totals have been in the $7-8 million range, still rather minuscule in the context of all publicly traded companies.
Charts courtesy of www.stockcharts.com
Thinly Traded Biotech Shows Signs of Accumulation - Friday, January 18, 2019
Biospecifics Technologies (BSTC +$0.18 or +0.27% to $66.51) posted a 4th consecutive gain but ended in the lower third of its intra-day range after highlighted in yellow with pivot point cited based on its 11/07/18 high plus 10 cents in the earlier mid-day report (read here).
The thinly traded Biomed/Biotech firm hit a new 52-week high on the prior session with its twice average volume, easily meeting the volume threshold of +40% above average volume which is necessary to trigger a proper technical buy signal. Its small supply (S criteria) of only 5.2 million shares in the public float can contribute to greater price volatility in the event of institutional buying or selling. Disciplined investors avoid chasing stocks more than +5% above prior highs and always limit losses by selling if ever a stock falls more than -7% from their purchase price.
The number of top-rated funds owning its shares rose from 171 in Mar '18 to 216 in Dec '18, a reassuring sign concerning the I criteria. Its current up/Down Volume Ratio of 1.5 is an unbiased indication its shares have been under accumulation over the past 50 days. It has an A Timeliness Rating and a C Sponsorship rating.
Earnings increases have been above the +25% minimum guideline (C criteria) in the 4 latest quarterly comparisons through Sep '18. Its sales revenues growth rate has shown acceleration, but quarterly totals have been in the $7-8 million range, still rather minuscule in the context of all publicly traded companies.
Charts courtesy of www.stockcharts.com